BRPI0412695A - derivados de quinolina e quinazolina dotados de afinidade para receptores do tipo 5ht1 - Google Patents

derivados de quinolina e quinazolina dotados de afinidade para receptores do tipo 5ht1

Info

Publication number
BRPI0412695A
BRPI0412695A BRPI0412695-5A BRPI0412695A BRPI0412695A BR PI0412695 A BRPI0412695 A BR PI0412695A BR PI0412695 A BRPI0412695 A BR PI0412695A BR PI0412695 A BRPI0412695 A BR PI0412695A
Authority
BR
Brazil
Prior art keywords
quinoline
quinazoline derivatives
receptor affinity
affinity
derivatives
Prior art date
Application number
BRPI0412695-5A
Other languages
English (en)
Inventor
Markus Bergauer
Barbara Bertani
Matteo Biagetti
Steven Mark Bromidge
Alessandro Falchi
Colin Philip Leslie
Giancarlo Merlo
Domenica Antonia Pizzi
Marilisa Rinaldi
Luigi Piero Stasi
Jessica Tibasco
Antonio Kuok Keong Vong
Simon Edward Ward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0412695A publication Critical patent/BRPI0412695A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Manufacturing & Machinery (AREA)
  • Neurosurgery (AREA)
  • Ceramic Engineering (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"DERIVADOS DE QUINOLINA E QUINAZOLINA DOTADOS DE AFINIDADE PARA RECEPTORES DO TIPO 5HT1". Os compostos de fórmula (I) e os sais farmaceuticamente aceitáveis dos mesmos são proporcionados: onde R~ 1~, m, X, R~ 2~, n, W, p, Y, Z, R~ 3~, R~ 4~, R~ 5~, e q apresentam os significados de acordo como definido na descrição. Os métodos de preparação e o uso dos mesmos em terapia, em particular para as desordens do SNC, tais como depressão ou ansiedade, são também descritos.
BRPI0412695-5A 2003-07-18 2004-07-15 derivados de quinolina e quinazolina dotados de afinidade para receptores do tipo 5ht1 BRPI0412695A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0316915.8A GB0316915D0 (en) 2003-07-18 2003-07-18 Compounds
PCT/EP2004/008000 WO2005014552A1 (en) 2003-07-18 2004-07-15 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors

Publications (1)

Publication Number Publication Date
BRPI0412695A true BRPI0412695A (pt) 2006-10-03

Family

ID=27764115

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412695-5A BRPI0412695A (pt) 2003-07-18 2004-07-15 derivados de quinolina e quinazolina dotados de afinidade para receptores do tipo 5ht1

Country Status (28)

Country Link
US (5) US7279481B2 (pt)
EP (3) EP1646613B1 (pt)
JP (1) JP2006528146A (pt)
KR (1) KR20060041242A (pt)
CN (1) CN100441571C (pt)
AR (1) AR046394A1 (pt)
AT (2) ATE448205T1 (pt)
AU (1) AU2004263268B2 (pt)
BR (1) BRPI0412695A (pt)
CA (1) CA2532452A1 (pt)
CY (1) CY1107974T1 (pt)
DE (2) DE602004024141D1 (pt)
DK (1) DK1646613T3 (pt)
ES (2) ES2302543T3 (pt)
GB (1) GB0316915D0 (pt)
HR (1) HRP20080226T3 (pt)
IL (1) IL173036A0 (pt)
IS (1) IS2744B (pt)
MA (1) MA27926A1 (pt)
MX (1) MXPA06000716A (pt)
NO (1) NO20060774L (pt)
NZ (1) NZ544586A (pt)
PL (1) PL1646613T3 (pt)
PT (1) PT1646613E (pt)
RU (1) RU2402533C2 (pt)
SI (1) SI1646613T1 (pt)
TW (1) TW200521115A (pt)
WO (1) WO2005014552A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7504395B2 (en) 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7507735B2 (en) * 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
KR100817538B1 (ko) * 2006-07-05 2008-03-27 한국화학연구원 신규 치환된―１ｈ―퀴나졸린―２,４―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물
MX2009006672A (es) * 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
WO2008095086A2 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
DE602007012683D1 (de) 2007-07-19 2011-04-07 Esteve Labor Dr Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente
JP2010537990A (ja) * 2007-08-27 2010-12-09 ユニバーシティ オブ バージニア パテント ファウンデーション アルコール中毒および薬物嗜癖の処置のための医薬の組み合わせ
KR20100127799A (ko) 2008-02-28 2010-12-06 유니버시티 오브 버지니아 페이턴트 파운데이션 세로토닌 운반체 유전자 및 알콜중독의 치료
CA2722326A1 (en) 2008-04-24 2009-10-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
DE602008004213D1 (de) * 2008-05-06 2011-02-10 Biedermann Motech Gmbh Stangenförmiges Implantat, insbesondere zur dynamischen Stabilisierung der Wirbelsäule
US20100298397A1 (en) * 2009-05-19 2010-11-25 Singh Nikhilesh N Method of treatment of obsessive compulsive disorder with ondansetron
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
EP2308850A1 (en) * 2009-10-06 2011-04-13 Laboratorios Del. Dr. Esteve, S.A. Heterocycyl-substituted-alkylamino phenyl derivatives, their preparation and use as medicaments
PL2801625T3 (pl) 2010-07-02 2018-06-29 University Of Virginia Patent Foundation Molekularne, genetyczne podejście do leczenia i diagnozy uzależnienia od alkoholu i leków
BR112014002939A2 (pt) 2011-08-09 2017-03-01 Takeda Pharmaceuticals Co composto, medicamento, método para profilaxia ou tratamento de doença, a doença sendo esquizofrenia, alzheimer, parkinson ou huntington, uso do composto, e, método para inibir o lsd1
EP2751137A4 (en) 2011-09-09 2015-06-03 Univ Virginia Patent Found MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG INDEPENDENCE
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013169964A1 (en) * 2012-05-09 2013-11-14 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN103508927A (zh) * 2012-06-25 2014-01-15 天津药物研究院 一种2-甲磺酰氨基二苯醚的制备方法
EP2907802B1 (en) 2012-10-12 2019-08-07 Takeda Pharmaceutical Company Limited Cyclopropanamine compound and use thereof
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
DK3072884T3 (da) 2013-11-20 2020-03-09 Sanwa Kagaku Kenkyusho Co 3-azabicyclo[3.1.0]hexanderivat og anvendelse deraf til medicinske formål
NZ725262A (en) 2014-04-11 2023-01-27 Takeda Pharmaceuticals Co Cyclopropanamine compound and use thereof
FR3028527A1 (fr) 2014-11-13 2016-05-20 Pivert Identification de facteurs de transcription de yarrowia lipolytica
WO2016075314A1 (fr) 2014-11-13 2016-05-19 Institut National De La Recherche Agronomique Identification de facteurs de transcription de yarrowia lipolytica affectant la production de proteines
DK3193901T3 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd PIRIN POLYPEPTIDE AND IMMUNMODULATION
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
EP3662917A1 (en) 2015-06-15 2020-06-10 4D Pharma Research Limited Compositions comprising bacterial strains
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
MX373290B (es) 2016-03-04 2020-06-18 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PL3638271T3 (pl) 2017-06-14 2021-03-22 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
CN108047143A (zh) * 2017-12-18 2018-05-18 刘凤娟 一种用于治疗功能性胃肠病的5-羟色胺受体拮抗剂的合成方法
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
SG11202012973RA (en) 2018-06-27 2021-01-28 Bristol Myers Squibb Co Naphthyridinone compounds useful as t cell activators
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
CA3162979A1 (en) 2019-12-23 2021-07-01 Upender Velaparthi Substituted piperazine derivatives useful as t cell activators
IL294148A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinazolinyl compounds are useful as t-cell activators
CN118308475B (zh) * 2024-03-18 2024-11-26 安徽医科大学第一附属医院 Htr1b作为胚胎发育停滞的诊断标志物和治疗靶点方面的应用
WO2026056874A1 (en) * 2024-09-12 2026-03-19 National Institute Of Biological Sciences, Beijing Sarm1 activators and use thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2641602A (en) 1950-11-29 1953-06-09 Eastman Kodak Co 1, 8-dihydroxy-5-nitro-4-hydroxyethylphenyl aminoanthraquinone compounds
US3937708A (en) 1971-06-07 1976-02-10 Boehringer Ingelheim Gmbh N-phenyl-imidazolidine-1-ones
US3975525A (en) 1971-06-07 1976-08-17 Boehringer Ingelheim Gmbh N-[4'-Imidazolidinon-(2)-yl-phenethyl]-N'-pyridyl-piperazines and salts thereof
US3992537A (en) 1971-06-07 1976-11-16 Boehringer Ingelheim Gmbh Pharmaceutical compositions containing an N-phenyl-imidazolidine-2-one and method of use
JPS5883677A (ja) 1981-11-11 1983-05-19 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
US4891275A (en) * 1982-10-29 1990-01-02 Norsk Hydro A.S. Aluminum shapes coated with brazing material and process of coating
JPS6354363A (ja) 1986-08-26 1988-03-08 Ss Pharmaceut Co Ltd キノリン誘導体
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US4891375A (en) 1988-01-13 1990-01-02 Pfizer Inc. Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
JP2777159B2 (ja) 1988-12-22 1998-07-16 エーザイ株式会社 環状アミン誘導体を含有する医薬
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
NZ240863A (en) * 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
GB9300195D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
GB9308725D0 (en) 1993-04-27 1993-06-09 Wyeth John & Brother Ltd Piperazine derivatives
PT889889E (pt) * 1996-03-29 2007-01-31 Duphar Int Res Composto de piperazina e piperidina
US5965560A (en) 1996-04-30 1999-10-12 Warner-Lambert Company Substituted piperazines and piperidines as central nervous system agents
GB2312843A (en) 1996-05-07 1997-11-12 Merck & Co Inc Method of treating rheumatoid arthritis
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
EP0900792B1 (en) * 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
DE69819266T2 (de) 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
KR100607838B1 (ko) 1997-10-27 2006-08-04 뉴로서치 에이/에스 니코틴 작용성 아세틸콜린 수용체상의 콜린 작용성 리간드로서의 호모피페라진 유도체 및 이를 포함하는 약제학적 조성물
CA2313125A1 (en) * 1997-12-12 1999-06-24 Laramie Mary Gaster Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
UA62015C2 (en) * 1998-12-28 2003-12-15 Pfizer Prod Inc Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
AU5567000A (en) 1999-06-24 2001-01-09 Toray Industries, Inc. Alpha1b-adrenergic receptor antagonists
ES2234683T3 (es) 1999-11-05 2005-07-01 Smithkline Beecham Plc Derivados de isoquinolina y quinazolina con actividad combinada sobre los receptores 5ht1a, 5ht1b y 5ht1d.
US6939871B2 (en) 2000-10-26 2005-09-06 Smithkline Beecham P.L.C. Benzoxazinone derivatives, their preparation and use
CA2364211A1 (en) 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
GB0106419D0 (en) * 2001-03-15 2001-05-02 Smithkline Beecham Plc Novel compounds
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
GB0203804D0 (en) 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
CA2505397A1 (en) 2002-11-08 2004-05-21 Warner-Lambert Company Llc Phenylalkyl and pyridylalkyl piperazine derivatives
GB0227240D0 (en) 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
MXPA06009892A (es) 2004-03-10 2007-03-01 Altana Pharma Ag Nuevas hidroxi-6-fenilfenantridinas sustituidas con amido y su uso como inhibidores de la fosfodiesterasa tipo 4 (pde4).
PE20060653A1 (es) 2004-08-31 2006-09-27 Glaxo Group Ltd Derivados triciclicos condensados como moduladores del receptor 5-ht1

Also Published As

Publication number Publication date
US20090312546A1 (en) 2009-12-17
ATE389637T1 (de) 2008-04-15
MXPA06000716A (es) 2006-03-30
DE602004012564D1 (de) 2008-04-30
KR20060041242A (ko) 2006-05-11
US20070167423A1 (en) 2007-07-19
ES2336148T3 (es) 2010-04-08
SI1646613T1 (sl) 2008-08-31
PL1646613T3 (pl) 2008-08-29
CA2532452A1 (en) 2005-02-17
TW200521115A (en) 2005-07-01
NZ544586A (en) 2009-05-31
EP1876174A1 (en) 2008-01-09
CN100441571C (zh) 2008-12-10
HK1089438A1 (en) 2006-12-01
US7279481B2 (en) 2007-10-09
EP2145622A1 (en) 2010-01-20
ES2302543T3 (es) 2008-07-16
JP2006528146A (ja) 2006-12-14
AU2004263268A1 (en) 2005-02-17
CY1107974T1 (el) 2013-09-04
RU2006104993A (ru) 2006-08-10
DE602004024141D1 (de) 2009-12-24
PT1646613E (pt) 2008-06-19
NO20060774L (no) 2006-04-06
IS8304A (is) 2006-02-15
MA27926A1 (fr) 2006-06-01
EP1646613A1 (en) 2006-04-19
DE602004012564T2 (de) 2009-04-30
ATE448205T1 (de) 2009-11-15
WO2005014552A1 (en) 2005-02-17
US20080280919A1 (en) 2008-11-13
CN1852896A (zh) 2006-10-25
US7592346B2 (en) 2009-09-22
AU2004263268B2 (en) 2010-12-16
US7732600B2 (en) 2010-06-08
EP1646613B1 (en) 2008-03-19
US20100204273A1 (en) 2010-08-12
RU2402533C2 (ru) 2010-10-27
US20060229312A1 (en) 2006-10-12
DK1646613T3 (da) 2008-07-14
IL173036A0 (en) 2006-06-11
US7459456B2 (en) 2008-12-02
IS2744B (is) 2011-08-15
HRP20080226T3 (en) 2008-06-30
AR046394A1 (es) 2005-12-07
GB0316915D0 (en) 2003-08-20
EP1876174B1 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
MXPA06000716A (es) Derivados de quinolina y quinazolina que tienen afinidad hacia receptores del tipo 5ht1.
UY27760A1 (es) Nuevos derivados de pirrolidinio.
BR0114754A (pt) Compostos não-imidazóis
MY130803A (en) New quinuclidine amide derivatives
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
UY27807A1 (es) Nuevos derivados de piridazin-3(2h)-ona
BR0214891A (pt) Herbicidas
BR0211805A (pt) Herbicidas
BR0112756A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina, de congestão nasal, asma alérgica, e rinite alérgica, e, uso de um composto
BRPI0417478A (pt) 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina
SE0101387D0 (sv) Novel compounds
BR0014279A (pt) Derivados de piperazina como antagonistas 5-ht1b
BR0210538A (pt) Derivados de 5-halotriptamina usados como ligantes dos receptores de serotonina 5-ht6 e/ou 5-ht7
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
UY27850A1 (es) Nuevos carbamatos de quinuclidina y composiciones farmacéuticas que los contienen
SE0104250D0 (sv) Heterocyclic compounds
DE60121461D1 (de) Kondensierte pyridoindolderivate
ATE540948T1 (de) Pyrrolopyridine als proteinkinasehemmer
DE69838662D1 (de) Morphinanderivate und ihre medizinische Anwendung
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ES2249309T3 (es) Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
BRPI0409002A (pt) pirazóis 1,3,4-substituìdos para uso como antagonistas receptores 5h-t no tratamento de psicoses e distúrbios neurológicos
BR0315995A (pt) Composto, uso de um composto composição farmacêutica, métodos para a terapia da dor, de distúrbios gastrointestinais, e da ansiedade em um animal de sangue quente, e, processo para preparar um composto
DE60224723D1 (de) Therapeutische heterocyclen als bradykinin b2 rezeptor antagonisten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA.INT.CI. C07D 215/38, C07D 401/12, C07D 405/12,C07D 409/12, C07D 413/12, A61P 25/00, A61P 25/22, A61P 25/24

Ipc: C07D 215/38 (2011.01), C07D 413/12 (2011.01), C07D

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.